Junshi's PD-1 Approved for Third Indication in China, Bladder Cancer

Shanghai Junshi Bio announced China 's NMPA approved a third indication for the company's PD-1 drug. Toripalimab is now approved as a second-line therapy for locally advanced or metastatic urothelial carcinoma in patients who failed platinum-based chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum chemotherapy. Previously, toripalimab was approved as a second-line treatment for metastatic melanoma and a third-line therapy for nasopharyngeal carcinoma. More details.... Stock Symbols: (HK: 1877; SHA: 688180) Share this with colleagues: // //